Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

被引：51

作者：

Cipponi, Arcadi ^{[1
]}

Wieers, Gregoire ^{[1
,2
]}

van Baren, Nicolas ^{[1
,2
]}

Coulie, Pierre G. ^{[1
]}

机构：

[1] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium

[2] Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium

来源：

CANCER IMMUNOLOGY IMMUNOTHERAPY | 2011年 / 60卷 / 08期

关键词：

Melanoma; T lymphocyte; Immunotherapy; Prognosis; PIVAC; 10; REGULATORY T-CELLS; CUTANEOUS MALIGNANT-MELANOMA; HUMAN REGRESSIVE MELANOMA; CLINICAL STAGE-I; METASTATIC MELANOMA; PROGNOSTIC-SIGNIFICANCE; IMMUNE SURVEILLANCE; COLORECTAL-CANCER; EXPRESSION; RECEPTOR;

D O I：

10.1007/s00262-011-1026-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumor-infiltrating T lymphocytes (TILs) are observed in a number of human primary or metastatic tumors. Recently, gene expression profiling experiments suggested that the presence of T cells in metastatic melanomas before vaccinating the patients with tumor antigens could be a biomarker for clinical benefit from the vaccines. In this context, we review results pertaining to TILs in human melanomas, their prognostic value, and some possible reasons why their presence could help in selecting melanoma patients for vaccination against tumor-specific antigens.

引用

页码：1153 / 1160

页数：8

共 73 条

[51] USE OF TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN THE IMMUNOTHERAPY OF PATIENTS WITH METASTATIC MELANOMA - A PRELIMINARY-REPORT [J].

ROSENBERG, SA ;

PACKARD, BS ;

AEBERSOLD, PM ;

SOLOMON, D ;

TOPALIAN, SL ;

TOY, ST ;

SIMON, P ;

LOTZE, MT ;

YANG, JC ;

SEIPP, CA ;

SIMPSON, C ;

CARTER, C ;

BOCK, S ;

SCHWARTZENTRUBER, D ;

WEI, JP ;

WHITE, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (25) :1676-1680

[52] Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes [J].

Rosenberg, SA ;

Dudley, ME .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 :14639-14645

[53] Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma [J].

Straten, P ;

Becker, JC ;

Seremet, T ;

Brocker, EB ;

Zeuthen, J .

JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02) :279-284

[54]

STROHAL R, 1994, CANCER RES, V54, P4734

[55] Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma [J].

Taylor, Rebecca C. ;

Patel, Ami ;

Panageas, Katherine S. ;

Busam, Klaus J. ;

Brady, Mary S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :869-875

[56]

Tuthill RJ, 2002, AM J CLIN PATHOL, V118, P504

[57] Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase [J].

Uyttenhove, C ;

Pilotte, L ;

Théate, I ;

Stroobant, V ;

Colau, D ;

Parmentier, N ;

Boon, T ;

Van den Eynde, BJ .

NATURE MEDICINE, 2003, 9 (10) :1269-1274

[58]

Valmori D, 1999, CANCER RES, V59, P4050

[59] Tetramer-guided analysis of TCR β-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients [J].

Valmori, D ;

Dutoit, V ;

Liénard, D ;

Lejeune, F ;

Speiser, D ;

Rimoldi, D ;

Cerundolo, V ;

Dietrich, PY ;

Cerottini, JC ;

Romero, P .

JOURNAL OF IMMUNOLOGY, 2000, 165 (01) :533-538

[60]

Valmori D, 2000, CANCER RES, V60, P4499

← 1 2 3 4 5 6 7 8 →